Literature DB >> 30058111

Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations.

Susanna Naggie1, Meredith Clement1, Sam Lusk1, Anu Osinusi2, Tiffany Himmel3, Joseph E Lucas1, Will J Thompson4, Laura Dubois4, M Arthur Moseley4, Paul J Clark1,5, Shyam Kottilil6, Keyur Patel1,7.   

Abstract

PURPOSE: In the interferon era of hepatitis C virus (HCV) therapies, genotype/subtype, cirrhosis, prior treatment failure, sex, and race predicted relapse. Our objective is to validate a targeted proteomics platform of 17 peptides to predict sustained virologic response (SVR). EXPERIMENTAL
DESIGN: Stored plasma from three, open-label, trials of HIV/HCV-coinfected subjects receiving interferon-containing regimens is identified. LC-MS/MS is used to quantitate the peptides directly from plasma, and IL28B genotyping is completed using stored peripheral blood mononuclear cells (PBMC). A logistic regression model is built to analyze the probability of SVR using responders and nonresponders to interferon-based regimens.
RESULTS: The cohort (N = 35) is predominantly black (51.4%), male (86%), and with median age 48 years. Most patients achieve SVR (54%). Using multivariable models, it is verified that three human corticosteroid binding globulin (CBG) peptides are predictive of SVR in patients with the unfavorable IL28B genotypes (CT/TT). The model performs better than IL28B alone, with an area under the curve of 0.870. CONCLUSIONS AND CLINICAL RELEVANCE: In HIV/HCV-coinfected patients, three human CBG peptides that accurately predict treatment response with interferon-based therapy are identified. This study suggests that a stepwise approach combining a genetic predictor followed by targeted proteomics can improve the accuracy of clinical decision-making.
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  IL28B; hepatitis C virus; human Immunodeficiency virus; pharmacogenomics; proteomics

Mesh:

Substances:

Year:  2018        PMID: 30058111      PMCID: PMC6353701          DOI: 10.1002/prca.201800006

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  11 in total

1.  Skyline: an open source document editor for creating and analyzing targeted proteomics experiments.

Authors:  Brendan MacLean; Daniela M Tomazela; Nicholas Shulman; Matthew Chambers; Gregory L Finney; Barbara Frewen; Randall Kern; David L Tabb; Daniel C Liebler; Michael J MacCoss
Journal:  Bioinformatics       Date:  2010-02-09       Impact factor: 6.937

2.  Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.

Authors:  K Rajender Reddy; Marc Bourlière; Mark Sulkowski; Masao Omata; Stefan Zeuzem; Jordan J Feld; Eric Lawitz; Patrick Marcellin; Tania M Welzel; Robert Hyland; Xiao Ding; Jenny Yang; Steven Knox; Phillip Pang; Hadas Dvory-Sobol; G Mani Subramanian; William Symonds; John G McHutchison; Alessandra Mangia; Edward Gane; Masashi Mizokami; Stanislas Pol; Nezam Afdhal
Journal:  Hepatology       Date:  2015-05-09       Impact factor: 17.425

3.  Identification and Quantitation of Coding Variants and Isoforms of Pulmonary Surfactant Protein A.

Authors:  Matthew W Foster; J Will Thompson; Julie G Ledford; Laura G Dubois; John W Hollingsworth; Dave Francisco; Sasipa Tanyaratsrisakul; Dennis R Voelker; Monica Kraft; M Arthur Moseley; W Michael Foster
Journal:  J Proteome Res       Date:  2014-07-15       Impact factor: 4.466

4.  High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients.

Authors:  Keyur Patel; Joseph E Lucas; J Will Thompson; Laura G Dubois; Hans L Tillmann; Alexander J Thompson; Diane Uzarski; Robert M Califf; Martin A Moseley; Geoffrey S Ginsburg; John G McHutchison; Jeanette J McCarthy
Journal:  Hepatology       Date:  2011-05-14       Impact factor: 17.425

5.  Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

Authors:  Susanna Naggie; Curtis Cooper; Michael Saag; Kimberly Workowski; Peter Ruane; William J Towner; Kristen Marks; Anne Luetkemeyer; Rachel P Baden; Paul E Sax; Edward Gane; Jorge Santana-Bagur; Luisa M Stamm; Jenny C Yang; Polina German; Hadas Dvory-Sobol; Liyun Ni; Phillip S Pang; John G McHutchison; Catherine A M Stedman; Javier O Morales-Ramirez; Norbert Bräu; Dushyantha Jayaweera; Amy E Colson; Pablo Tebas; David K Wong; Douglas Dieterich; Mark Sulkowski
Journal:  N Engl J Med       Date:  2015-07-21       Impact factor: 91.245

6.  Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

Authors:  Kris V Kowdley; Stuart C Gordon; K Rajender Reddy; Lorenzo Rossaro; David E Bernstein; Eric Lawitz; Mitchell L Shiffman; Eugene Schiff; Reem Ghalib; Michael Ryan; Vinod Rustgi; Mario Chojkier; Robert Herring; Adrian M Di Bisceglie; Paul J Pockros; G Mani Subramanian; Di An; Evguenia Svarovskaia; Robert H Hyland; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; David Pound; Michael W Fried
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

7.  Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.

Authors:  Susanna Naggie; Anu Osinusi; Antonios Katsounas; Richard Lempicki; Eva Herrmann; Alexander J Thompson; Paul J Clark; Keyur Patel; Andrew J Muir; John G McHutchison; Joerg F Schlaak; Martin Trippler; Bhavana Shivakumar; Henry Masur; Michael A Polis; Shyam Kottilil
Journal:  Hepatology       Date:  2012-07-02       Impact factor: 17.425

8.  Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice.

Authors:  L I Backus; P S Belperio; T A Shahoumian; T P Loomis; L A Mole
Journal:  Aliment Pharmacol Ther       Date:  2016-06-13       Impact factor: 8.171

9.  Characterization of serum proteins associated with IL28B genotype among patients with chronic hepatitis C.

Authors:  Derek D Cyr; Joseph E Lucas; J Will Thompson; Keyur Patel; Paul J Clark; Alexander Thompson; Hans L Tillmann; John G McHutchison; M Arthur Moseley; Jeanette J McCarthy
Journal:  PLoS One       Date:  2011-07-05       Impact factor: 3.240

10.  All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.

Authors:  David R Nelson; James N Cooper; Jacob P Lalezari; Eric Lawitz; Paul J Pockros; Norman Gitlin; Bradley F Freilich; Ziad H Younes; William Harlan; Reem Ghalib; Godson Oguchi; Paul J Thuluvath; Grisell Ortiz-Lasanta; Mordechai Rabinovitz; David Bernstein; Michael Bennett; Trevor Hawkins; Natarajan Ravendhran; Aasim M Sheikh; Peter Varunok; Kris V Kowdley; Delphine Hennicken; Fiona McPhee; Khurram Rana; Eric A Hughes
Journal:  Hepatology       Date:  2015-03-10       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.